tiprankstipranks
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
US Market

Reviva Pharmaceuticals Holdings (RVPH) Stock Forecast & Price Target

1,211 Followers
See the Price Targets and Ratings of:

RVPH Analyst Ratings

Moderate Buy
4Ratings
Moderate Buy
2 Buy
2 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Reviva
Pharmaceuticals Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVPH Stock 12 Month Forecast

Average Price Target

$15.50
▲(1887.18% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Reviva Pharmaceuticals Holdings in the last 3 months. The average price target is $15.50 with a high forecast of $30.00 and a low forecast of $1.00. The average price target represents a 1887.18% change from the last price of $0.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","37":"$37","-1":"-$1","8.5":"$8.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,8.5,18,27.5,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.809,3.0544615384615383,5.2999230769230765,7.545384615384615,9.790846153846152,12.03630769230769,14.281769230769228,16.52723076923077,18.772692307692306,21.018153846153844,23.26361538461538,25.509076923076922,27.75453846153846,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.809,1.9390769230769234,3.0691538461538466,4.19923076923077,5.329307692307693,6.459384615384616,7.589461538461539,8.719538461538463,9.849615384615385,10.979692307692309,12.109769230769231,13.239846153846154,14.369923076923078,{"y":15.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.809,0.8236923076923077,0.8383846153846154,0.8530769230769231,0.8677692307692308,0.8824615384615385,0.8971538461538462,0.9118461538461539,0.9265384615384615,0.9412307692307693,0.9559230769230769,0.9706153846153847,0.9853076923076923,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.199,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.416,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.452,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.712,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.993,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.334,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.852,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.809,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$15.50Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on RVPH
Maxim Group
Maxim Group
Hold
Downgraded
04/08/26
Reviva Pharmaceuticals downgraded to Hold from Buy at MaximReviva Pharmaceuticals downgraded to Hold from Buy at Maxim
Roth MKM
$1.5$1
Buy
28.21%
Upside
Assigned
04/01/26
Reviva Pharmaceuticals Holdings (RVPH) Gets a Buy from Roth MKM
Alliance Global Partners Analyst forecast on RVPH
Alliance Global Partners
Alliance Global Partners
$16$30
Buy
3746.15%
Upside
Reiterated
03/30/26
Reviva Pharmaceuticals price target raised to $30 from $16 at Alliance GlobalReviva Pharmaceuticals price target raised to $30 from $16 at Alliance Global
D. Boral Capital Analyst forecast on RVPH
D. Boral Capital
D. Boral Capital
Hold
Downgraded
03/05/26
Reviva Pharmaceuticals downgraded to Hold from Buy at D. Boral CapitalReviva Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital
Chardan Capital Analyst forecast on RVPH
Chardan Capital
Chardan Capital
$40
Buy
5028.21%
Upside
Reiterated
01/05/26
Reviva Pharmaceuticals Holdings (RVPH) Receives a Buy from Chardan Capital
H.C. Wainwright Analyst forecast on RVPH
H.C. Wainwright
H.C. Wainwright
$80
Buy
10156.41%
Upside
Reiterated
12/23/25
Reviva Pharmaceuticals: Buy Rating Reaffirmed as Additional Phase 3 Trial Leaves Schizophrenia Launch and DCF‑Backed Upside Intact
Wolfe Research Analyst forecast on RVPH
Wolfe Research
Wolfe Research
$40
Buy
5028.21%
Upside
Initiated
09/29/25
Reviva Pharmaceuticals initiated with a Buy at ChardanReviva Pharmaceuticals initiated with a Buy at Chardan
Benchmark Co. Analyst forecast on RVPH
Benchmark Co.
Benchmark Co.
$280$140
Buy
17848.72%
Upside
Reiterated
09/15/25
Reviva Pharmaceuticals Holdings (RVPH) Gets a Buy from Benchmark Co.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on RVPH
Maxim Group
Maxim Group
Hold
Downgraded
04/08/26
Reviva Pharmaceuticals downgraded to Hold from Buy at MaximReviva Pharmaceuticals downgraded to Hold from Buy at Maxim
Roth MKM
$1.5$1
Buy
28.21%
Upside
Assigned
04/01/26
Reviva Pharmaceuticals Holdings (RVPH) Gets a Buy from Roth MKM
Alliance Global Partners Analyst forecast on RVPH
Alliance Global Partners
Alliance Global Partners
$16$30
Buy
3746.15%
Upside
Reiterated
03/30/26
Reviva Pharmaceuticals price target raised to $30 from $16 at Alliance GlobalReviva Pharmaceuticals price target raised to $30 from $16 at Alliance Global
D. Boral Capital Analyst forecast on RVPH
D. Boral Capital
D. Boral Capital
Hold
Downgraded
03/05/26
Reviva Pharmaceuticals downgraded to Hold from Buy at D. Boral CapitalReviva Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital
Chardan Capital Analyst forecast on RVPH
Chardan Capital
Chardan Capital
$40
Buy
5028.21%
Upside
Reiterated
01/05/26
Reviva Pharmaceuticals Holdings (RVPH) Receives a Buy from Chardan Capital
H.C. Wainwright Analyst forecast on RVPH
H.C. Wainwright
H.C. Wainwright
$80
Buy
10156.41%
Upside
Reiterated
12/23/25
Reviva Pharmaceuticals: Buy Rating Reaffirmed as Additional Phase 3 Trial Leaves Schizophrenia Launch and DCF‑Backed Upside Intact
Wolfe Research Analyst forecast on RVPH
Wolfe Research
Wolfe Research
$40
Buy
5028.21%
Upside
Initiated
09/29/25
Reviva Pharmaceuticals initiated with a Buy at ChardanReviva Pharmaceuticals initiated with a Buy at Chardan
Benchmark Co. Analyst forecast on RVPH
Benchmark Co.
Benchmark Co.
$280$140
Buy
17848.72%
Upside
Reiterated
09/15/25
Reviva Pharmaceuticals Holdings (RVPH) Gets a Buy from Benchmark Co.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Reviva Pharmaceuticals Holdings

3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-17.77%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -17.77% per trade.
1 Year
Jason McCarthyMaxim Group
Not Ranked
Success Rate
0/9 ratings generated profit
0%
Average Return
-70.56%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -70.56% per trade.
2 Years
xxx
Success Rate
0/9 ratings generated profit
0%
Average Return
-71.83%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -71.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVPH Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
7
6
4
4
3
Buy
0
0
0
0
1
Hold
1
7
10
11
9
Sell
0
0
0
3
7
Strong Sell
0
5
8
8
3
total
8
18
22
26
23
In the current month, RVPH has received 4 Buy Ratings, 9 Hold Ratings, and 10 Sell Ratings. RVPH average Analyst price target in the past 3 months is 15.50.
Each month's total comprises the sum of three months' worth of ratings.

RVPH Financial Forecast

RVPH Earnings Forecast

The previous quarter’s earnings for RVPH were $0.72.
The previous quarter’s earnings for RVPH were $0.72.
No data currently available

RVPH Sales Forecast

The previous quarter’s earnings for RVPH were $0.00.
The previous quarter’s earnings for RVPH were $0.00.

RVPH Stock Forecast FAQ

What is RVPH’s average 12-month price target, according to analysts?
Based on analyst ratings, Reviva Pharmaceuticals Holdings’s 12-month average price target is 15.50.
    What is RVPH’s upside potential, based on the analysts’ average price target?
    Reviva Pharmaceuticals Holdings has 1887.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RVPH a Buy, Sell or Hold?
          Reviva Pharmaceuticals Holdings has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Reviva Pharmaceuticals Holdings’s price target?
            The average price target for Reviva Pharmaceuticals Holdings is 15.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $1.00. The average price target represents 1887.18% Increase from the current price of $0.78.
              What do analysts say about Reviva Pharmaceuticals Holdings?
              Reviva Pharmaceuticals Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of RVPH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.